Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2010 Jan;235(1):3-9.
doi: 10.1258/ebm.2009.009191.

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway

Grzegorz Korpanty  1 , Elizabeth Smyth, Laura A Sullivan, Rolf A Brekken, Desmond N Carney
Affiliations
Review

Antiangiogenic therapy in lung cancer: focus on vascular endothelial growth factor pathway

Grzegorz Korpanty et al. Exp Biol Med (Maywood). 2010 Jan.

Abstract

Lung cancer (LC) is a leading cause of death worldwide. Recent advances in chemotherapeutic agents have not yielded any significant improvement in the prognosis of patients with LC. The five-year survival rate for all combined disease stages remains about 15%. For this reason, new therapies such as those that inhibit tumor angiogenesis or block activity of growth factor receptors are of special interest in this group of patients. In this review we will summarize the most recent clinical data on biologic therapies that inhibit tumor angiogenesis in LC, focusing on those that are most clinically relevant.

PubMed Disclaimer

Figures

Figure 1
Figure 1
VEGF pathway and the site of action of the inhibitors. VEGF, vascular endothelial growth factor. (A color version of this figure is available in the online journal)
See this image and copyright information in PMC

References

    1. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ. Cancer statistics, 2007. CA Cancer J Clin. 2007;57:43–66. - PubMed
    1. Spira A, Ettinger DS. Multidisciplinary management of lung cancer. N Engl J Med. 2004;350:379–92. - PubMed
    1. Read WL, Page NC, Tierney RM, Piccirillo JF, Govindan R. The epidemiology of bronchioloalveolar carcinoma over the past two decades: analysis of the SEER database. Lung Cancer. 2004;45:137–42. - PubMed
    1. Sanchez-Cespedes M, Ahrendt SA, Piantadosi S, Rosell R, Monzo M, Wu L, Westra WH, Yang SC, Jen J, Sidransky D. Chromosomal alterations in lung adenocarcinoma from smokers and nonsmokers. Cancer Res. 2001;61:1309–13. - PubMed
    1. Fong KM, Sekido Y, Gazdar AF, Minna JD. Lung cancer. 9: molecular biology of lung cancer: clinical implications. Thorax. 2003;58:892–900. - PMC - PubMed

Publication types

MeSH terms